Copenhagen, Denmark

Anker S Jorgensen


Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 161(Granted Patents)


Location History:

  • Kobenhavn O, DK (1991)
  • 2100 Kobenhavn O, DK (1995)
  • Kobenhavn, DK (2005)
  • Copenhagen, DK (1991 - 2010)

Company Filing History:


Years Active: 1991-2010

Loading Chart...
19 patents (USPTO):Explore Patents

Title: Anker S. Jorgensen: Innovator in Pharmaceutical Compounds

Introduction: Anker S. Jorgensen, based in Copenhagen, Denmark, is a notable inventor and innovator in the field of pharmaceuticals. With a remarkable portfolio of 19 patents, he has made significant contributions particularly in the development of new therapeutic compounds.

Latest Patents: Among his latest innovative works, Jorgensen has developed a novel class of compounds specifically targeting the modulation of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). These compounds, outlined in his patent, show potential for treating metabolic syndrome through their unique action. In another significant patent, he has introduced glucagon antagonists/inverse agonists, aimed at countering the effects of the glucagon hormone. These compounds may prove beneficial in managing conditions such as hyperglycemia, Type 1 and Type 2 diabetes, lipid metabolism disorders, and obesity.

Career Highlights: Anker S. Jorgensen has worked with prominent organizations, including Novo Nordisk A/S, where he has applied his expertise in pharmaceutical innovation. His career is marked by a commitment to advancing healthcare solutions through scientific research and development.

Collaborations: Throughout his career, Jorgensen has collaborated with esteemed colleagues, including Knud Erik Andersen and Ursula Sonnewald. These partnerships have fostered a creative environment for innovative thinking and development of new pharmaceutical solutions.

Conclusion: Anker S. Jorgensen's contributions to the pharmaceutical industry through his inventive work and patents are noteworthy. His ongoing research and development efforts promise to yield significant advancements in therapies, especially for metabolic and endocrine disorders. He exemplifies the spirit of innovation that drives the medical field forward.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…